Tang Capital group reports 6.6% Capricor (NASDAQ: CAPR) ownership on Schedule 13G
Rhea-AI Filing Summary
Tang Capital Management and related entities have disclosed a significant ownership position in Capricor Therapeutics, Inc. common stock. The group reports beneficial ownership of 3,399,900 shares of Capricor common stock, representing 6.6% of the outstanding shares as of the referenced date. All 3,399,900 shares are reported with shared voting and shared dispositive power, and no shares are reported with sole voting or dispositive power.
Within the group, Tang Capital Partners, LP reports 2,337,350 shares, or 4.5% of the class, and Tang Capital Partners International, LP reports 1,062,550 shares, or 2.1% of the class. Kevin Tang is identified as sharing voting and dispositive power with the Tang Capital entities. The filing is made on Schedule 13G, and the reporting persons certify that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Capricor Therapeutics.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What ownership stake in Capricor Therapeutics (CAPR) does Tang Capital report?
Tang Capital Management and related entities report beneficial ownership of 3,399,900 shares of Capricor Therapeutics common stock, representing 6.6% of the outstanding shares.
Which entities are included in the Tang Capital reporting group for CAPR?
The reporting group includes Tang Capital Management, LLC, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., Tang Capital Partners IV, Inc., and Kevin Tang.
Is Tang Capital’s CAPR ownership reported as a passive investment?
Yes. The reporting persons certify that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Capricor Therapeutics.